BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress
July 27, 2016 14:30 ET
|
BioMarin Pharmaceutical Inc.
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10% No Clinically Relevant Sustained Rises in ALT Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval...
BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th
July 21, 2016 16:03 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene...
BioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg
July 18, 2016 08:31 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...
BioMarin to Host Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4 at 4:30pm ET
July 14, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
June 20, 2016 16:35 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for...
BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe
May 31, 2016 16:05 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization...
BioMarin to Attend Upcoming Investor Conferences
May 04, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
- Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas - Goldman Sachs 37th Annual Global Healthcare Conference on June 9 in Ranchos Palos Verdes,...
BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease
May 03, 2016 08:25 ET
|
BioMarin Pharmaceutical Inc.
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin...
BioMarin Announces First Quarter 2016 Financial Results
April 28, 2016 16:01 ET
|
BioMarin Pharmaceutical Inc.
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million -Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim...
BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)
April 21, 2016 16:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an...